Findings

What do systematic reviews say?

82 questions · 90 findings · 10 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 15 · 16.7%GRADE not reported 4 · 4.4%Very low 14 · 15.6%Low 39 · 43.3%Moderate 16 · 17.8%High 2 · 2.2%

Tacrolimus 0.1% vs mometasone furoate ointment

Primary outcome 3: Adverse events · people with moderate to severe chronic relapsing dyshidrotic eczema on hands

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Moderate

Tacrolimus 0.1% vs mometasone furoate ointment

Secondary: investigator‐rated reduction in severity ‐ DASIb · people with moderate to severe chronic relapsing dyshidrotic eczema on hands

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Moderate

Tacrolimus 0.1% vs vehicle

Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

Topical calcineurin inhibitors: tacrolimus 0.1% ointment probably leads to higher primary: investigator‐rated good/excellent control of symptoms compared with vehicle (moderate certainty).

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
RR 29 [1.9, 443.25]
1 study · 28 participants
Moderate

Tacrolimus 0.1% vs vehicle

Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tacrolimus 0.1% vs vehicle

Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
RR 9 [0.53, 152.93]
1 study · 28 participants
Moderate

Tacrolimus 0.1% vs vehicle

Secondary: investigator‐rated reduction in severity ‐ Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

Eating a normally varied diet · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
No studies reported this outcome.
0 studies
No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

Restoration of sexual activity · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
None of the included studies assessed the effectiveness of treatments of genital ELP; thus, this outcome was not reported.
0 studies
No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

Reduction in number of flares · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
No studies reported this outcome.
0 studies
No studies found

Any topical or systemic intervention (topical/systemic steroids, ciclosporin, tacrolimus, retinoids, anti-malarials, biologics, phototherapy, surgery) vs Placebo, no treatment, another active intervention, or a different dose of the same intervention

Reduction in severity of flares · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
No studies reported this outcome.
0 studies
No studies found

Intervention not reported

Tacrolimus plus glucocorticosteroids · people undergoing liver transplantation

1 finding from 1 review

Maintenance immunosuppression for adults undergoing liver transplantation: a network meta‐analysis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Intervention not reported

Tacrolimus plus mycophenolate plus glucocorticosteroids · people undergoing liver transplantation

It is very uncertain whether the intervention changes tacrolimus plus mycophenolate plus glucocorticosteroids (very low certainty).

1 finding from 1 review

Maintenance immunosuppression for adults undergoing liver transplantation: a network meta‐analysis 2017 · Cochrane Headline outcomes only
HR 0.58 [0.14, 1.91]
1 study · 195 participants
Very low

Intervention not reported

Tacrolimus plus sirolimus · people undergoing liver transplantation

The intervention may leads to higher tacrolimus plus sirolimus (low certainty).

1 finding from 1 review

Maintenance immunosuppression for adults undergoing liver transplantation: a network meta‐analysis 2017 · Cochrane Headline outcomes only
HR 2.76 [1.3, 6.69]
1 study · 222 participants
Low

Intervention not reported

Tacrolimus plus azathioprine · people undergoing liver transplantation

It is very uncertain whether the intervention changes tacrolimus plus azathioprine (very low certainty).

1 finding from 1 review

Maintenance immunosuppression for adults undergoing liver transplantation: a network meta‐analysis 2017 · Cochrane Headline outcomes only
HR 0.46 [0.17, 1.15]
1 study · 97 participants
Very low

Intervention not reported

Tacrolimus plus everolimus · people undergoing liver transplantation

It is very uncertain whether the intervention changes tacrolimus plus everolimus (very low certainty).

1 finding from 1 review

Maintenance immunosuppression for adults undergoing liver transplantation: a network meta‐analysis 2017 · Cochrane Headline outcomes only
HR 1.43 [0.63, 3.38]
1 study · 488 participants
Very low

Topical triamcinolone acetonide vs Topical tacrolimus

Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment

Topical triamcinolone acetonide may leads to lower adverse effects compared with topical tacrolimus (low certainty).

1 finding from 1 review

Interventions for treating oral lichen planus: corticosteroid therapies 2020 · Cochrane All outcomes
3-8 weeks
RR 0.47 [0.22, 0.99]
2 studies · 58 participants
Low

Topical clobetasol propionate vs Topical tacrolimus

Pain (mean VAS score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment

Topical clobetasol propionate showed no clear difference in pain (mean VAS score) compared with topical tacrolimus; GRADE not reported.

1 finding from 1 review

Interventions for treating oral lichen planus: corticosteroid therapies 2020 · Cochrane All outcomes
end of treatment
MD 0.08 [-0.33, 0.49]
1 study · 68 participants
GRADE not reported

Topical clobetasol propionate vs Topical tacrolimus

Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment

It is very uncertain whether topical clobetasol propionate changes clinical resolution compared with topical tacrolimus (very low certainty).

1 finding from 1 review

Interventions for treating oral lichen planus: corticosteroid therapies 2020 · Cochrane All outcomes
3-8 weeks
RR 0.61 [0.38, 0.99]
2 studies · 52 participants
Very low

Topical triamcinolone acetonide vs Topical tacrolimus

Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment

It is very uncertain whether topical triamcinolone acetonide changes clinical resolution compared with topical tacrolimus (very low certainty).

1 finding from 1 review

Interventions for treating oral lichen planus: corticosteroid therapies 2020 · Cochrane All outcomes
3-8 weeks
RR 0.86 [0.55, 1.35]
2 studies · 60 participants
Very low

Topical clobetasol propionate vs Topical tacrolimus

Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment

It is very uncertain whether topical clobetasol propionate changes adverse effects compared with topical tacrolimus (very low certainty).

1 finding from 1 review

Interventions for treating oral lichen planus: corticosteroid therapies 2020 · Cochrane All outcomes
3-8 weeks
RR 0.05 [0.00, 0.83]
2 studies · 100 participants
Very low